NCT05597709Recruiting
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study
Source: ClinicalTrials.gov · Last updated 28 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2900 (estimated)
- First submitted
- 24 Oct 2022
- Start date
- 1 Jul 2022
- Primary completion date
- 1 Jun 2023
- Lead sponsor
- Wuxi Hisky Medical Technology Co Ltd
- NCT number
- NCT05597709
What you commit to
- Study type: Observational
- Planned participants: 2900
- From 1 Jul 2022 to the primary completion date, 1 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other types of diabetes
Other
- Patients unable to receive regular follow-up
Who the study is looking for
- Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
- UAP were measured based on iLivTouch
- Willing to attend this study and able to provide the written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongda Hospital, Medical School, Southeast University Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
Related publications
- Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China.Front Endocrinol (Lausanne) · 2024 · PMID 39698035
This page is information, not medical advice. Discuss any trial with your doctor.